[{"address1": "6000 Shoreline Court", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 243 6300", "fax": "650 243 6388", "website": "https://www.veracyte.com", "industry": "Diagnostics & Research", "sector": "Healthcare", "longBusinessSummary": "Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 815, "companyOfficers": [{"maxAge": 1, "name": "Mr. Marc A. Stapley", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1553250, "exercisedValue": 0, "unexercisedValue": 67159}, {"maxAge": 1, "name": "Ms. Rebecca  Chambers", "age": 45, "title": "Executive VP & CFO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 901493, "exercisedValue": 0, "unexercisedValue": 24622}, {"maxAge": 1, "name": "Dr. Phillip G. Febbo M.D.", "age": 57, "title": "Chief Scientific & Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 657741, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  McGuire", "age": 42, "title": "Executive VP, General Counsel & Chief People Officer", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 791723, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John  Leite Ph.D.", "age": 51, "title": "Chief Commercial Officer for CLIA Business", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1530634, "exercisedValue": 0, "unexercisedValue": 103573}, {"maxAge": 1, "name": "Mr. Jonathan  Wygant", "age": 52, "title": "VP & Chief Accounting Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steven  French", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Possemato", "title": "Senior Vice President of Corporate Marketing, Communications & Commercial Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Brainin", "age": 51, "title": "Executive VP & Chief Business Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Corinne  Danan", "title": "Senior Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 3, "compensationRisk": 7, "shareHolderRightsRisk": 4, "overallRisk": 5, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 32.97, "open": 33.0, "dayLow": 32.48, "dayHigh": 33.91, "regularMarketPreviousClose": 32.97, "regularMarketOpen": 33.0, "regularMarketDayLow": 32.48, "regularMarketDayHigh": 33.91, "beta": 1.665, "forwardPE": 96.588234, "volume": 377587, "regularMarketVolume": 377587, "averageVolume": 933315, "averageVolume10days": 751770, "averageDailyVolume10Day": 751770, "bid": 32.81, "ask": 32.9, "bidSize": 200, "askSize": 100, "marketCap": 2522509312, "fiftyTwoWeekLow": 18.61, "fiftyTwoWeekHigh": 35.51, "priceToSalesTrailing12Months": 6.3129177, "fiftyDayAverage": 30.4631, "twoHundredDayAverage": 24.857475, "currency": "USD", "enterpriseValue": 2307433216, "profitMargins": -0.13524, "floatShares": 76463397, "sharesOutstanding": 76812096, "sharesShort": 3496212, "sharesShortPriorMonth": 3109757, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.045500003, "heldPercentInsiders": 0.00818, "heldPercentInstitutions": 1.05161, "shortRatio": 4.49, "shortPercentOfFloat": 0.0508, "bookValue": 14.757, "priceToBook": 2.2253845, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -54041000, "trailingEps": -0.74, "forwardEps": 0.34, "enterpriseToRevenue": 5.775, "enterpriseToEbitda": 71.697, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "VCYT", "underlyingSymbol": "VCYT", "shortName": "Veracyte, Inc.", "longName": "Veracyte, Inc.", "firstTradeDateEpochUtc": 1383139800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0ed080f4-1811-3c23-a041-70d21c58c2b4", "gmtOffSetMilliseconds": -14400000, "currentPrice": 32.84, "targetHighPrice": 41.0, "targetLowPrice": 26.0, "targetMeanPrice": 35.0, "targetMedianPrice": 35.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 235915008, "totalCashPerShare": 3.071, "ebitda": 32183000, "totalDebt": 20838000, "quickRatio": 3.957, "currentRatio": 4.439, "totalRevenue": 399579008, "debtToEquity": 1.84, "revenuePerShare": 5.378, "returnOnAssets": 0.0037599998, "returnOnEquity": -0.04879, "freeCashflow": 46864752, "operatingCashflow": 50332000, "revenueGrowth": 0.267, "grossMargins": 0.67673, "ebitdaMargins": 0.08054, "operatingMargins": 0.04724, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-07"}]